Development and Applications of Bioorthogonal Chemistry
生物正交化学的发展与应用
基本信息
- 批准号:8759491
- 负责人:
- 金额:$ 35.15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-04-01 至 2018-06-30
- 项目状态:已结题
- 来源:
- 关键词:1-hexeneAgonistAlkenesAlkynesAmino AcidsAnimalsArrestinsBacteriophagesBiocompatibleCellsChemicalsChemistryColorConfocal MicroscopyCouplingCysteineDevelopmentDiabetes MellitusEnergy TransferEnteroglucagonEnvironmentEquilibriumExtracellular DomainFluoresceinFluorescent ProbesFumaratesFundingG Protein-Coupled Receptor GenesGeneticGlucagonGoalsHalf-LifeHandHydroquinonesIn SituKineticsLabelLasersLifeLigandsLysineMeasuresMediatingMicroscopeMonitorMovementMutagenesisN-terminalNitrilesNucleic Acid Regulatory SequencesObesityOpticsOrganismPalladiumPeptidesPerfusionPharmacologic SubstancePhenylhydrazinesPhysical condensationPhysiologic pulsePositioning AttributePropertyProteinsReactionReceptor ActivationRegulationReporterScanningSignal TransductionSignaling ProteinSiteSpecificitySurfaceSystemTechniquesTetrazolesTherapeutic AgentsTimeazobenzenebasebiomaterial compatibilityconformational conversioncycloadditionextracellularfluorophoreglucagon-like peptide 1insightirradiationmembermutantnext generationnovelphenylalanine analogphenylhydrazinepublic health relevancereceptorreceptor functiontooltwo-photon
项目摘要
DESCRIPTION (provided by applicant): Development and Applications of Bioorthogonal Chemistry ABSTRACT A major hurdle in biophysical studies of class B GPCR conformational transitions, particularly the movements of the two large domains during ligand-induced activation, is that there are very few techniques available that allow site-specific introduction o biophysical probes into these two domains without altering the receptor function. To overcome this limitation, our long-term goal is to develop bioorthogonal chemistry tools that enable biophysical studies of the multi-domain signaling proteins such as class B GPCRs in living cells. In our previous studies, we have optimized a bioorthogonal, photoinduced tetrazole-alkene cycloaddition reaction ('photoclick chemistry'), and developed the palladium-mediated cross-coupling reactions for selective protein labeling in living systems as well as a phage-assisted interrogation of reactivity strategy for evolving the sequence-specific bioorthogonal reactions. Built upon these results, in this application we plan to integrate the bioorthogonal chemistry tools with the genetic encoding of unique chemical functionalities to generate in situ the chemically modified GLP-1R/GCGR¿two members of the class B GPCRs that are implicated in diabetes and obesity, and study their conformational transitions and photo-regulation in living cells. The specific aims are as follows: 1) Apply photoclick chemistry to generate in situ the environment-sensitive fluorescent probes on GCGR/GLP-1R and probe the ligand-induced conformational changes in living cells. A spiro[2,3]hex-1-ene or fumarate-derived lysine will be site-specifically incorporated at the extracellular loop 3 region of GCGR/GLP- 1R to direct the photoclick chemistry, and the resulting fluorescent labeled GCGR/GLP-1R will be used in the studies of the conformational transitions induced by the specific ligands; 2) Develop binary bioorthogonal chemistry for dual-labeling of GCGR/GLP-1R to probe the ligand-induced conformational changes by FRET in living cells. The photoclick chemistry will be used in tandem with the sequence-specific palladium-mediated cross-coupling or the cysteine-nitrile condensation reaction to enable the simultaneous introduction of two fluorophores at the juxtamembrane domain and the N-terminal extracellular domain, respectively. The dynamic movements of these two interconnected domains upon perfusion of the specific peptide ligand in living cells will be monitored by FRET using confocal microscope; 3) Develop the azobenzene-based optochemical genetic tools for optical regulation of GLP-1R activation in living cells. A biocompatible inverse azo-coupling reaction based on the condensation of phenylhydrazines with fluoroquinols will be developed, which together with the genetic encoding of fluoroquinolalanine, will allow us to introduce the azobenzenes site-specifically into the two regulatory regions of GLP-1R. The effect of reversible photoswitching on GLP-1R activity in the absence or presence of GLP-1 will be assessed using b-arrestin-mCherry as a reporter for receptor activation. These studies will provide the key insights into GLP-1R/GCGR activation mechanisms, which are crucial for the development of GLP-1R/GCGR dual agonists as therapeutic agents for the treatment of diabetes and obesity.
描述(申请人提供):生物正交化学的发展和应用摘要在B类GPCR构象转变的生物物理研究中的一个主要障碍,特别是在配体诱导的激活过程中两个大结构域的移动,是很少有可用的技术允许在不改变受体功能的情况下将特定部位的生物物理探针引入这两个结构域。为了克服这一限制,我们的长期目标是开发生物正交化学工具,使活细胞中的多结构域信号蛋白(如B类GPCRs)能够进行生物物理研究。在我们之前的研究中,我们优化了生物正交光诱导的四氮唑-烯烃环加成反应(光点击化学),并开发了钯介导的交叉偶联反应用于生物系统中选择性的蛋白质标记,以及噬菌体辅助的反应策略的询问,以形成序列特异性的生物正交反应。在这些结果的基础上,在这一应用中,我们计划将生物正交化学工具与独特化学功能的遗传编码相结合,以原位生成化学修饰的GLP-1R/GCGR?两个与糖尿病和肥胖症有关的B类GPCR成员,并研究它们在活细胞中的构象转变和光调节。具体目的如下:1)应用光点化学法在GCGR/GLP-1R上原位产生环境敏感的荧光探针,并探测配体诱导的活细胞构象变化。将螺环[2,3]己烯或富马酸衍生的赖氨酸定点掺入GCGR/GLP-1R的胞外环3区域以指导光点击化学,得到的荧光标记的GCGR/GLP-1R将用于研究特定配体诱导的构象转变;2)建立双标记GCGR/GLP-1R的生物正交化学,以探测活细胞中FRET诱导的配体诱导的构象变化。光点化学将与序列特异性的钯介导的交叉偶联或半胱氨酸-腈缩合反应一起使用,以使两个荧光团分别在膜旁区域和N-末端胞外区域同时引入。这两个相互连接的结构域在活细胞中灌流特定的多肽配体后的动态移动将通过FRET使用共聚焦显微镜进行监测;3)开发基于偶氮苯的光化学遗传工具,用于光调控活细胞中GLP-1R的激活。我们将开发一种基于苯肼和氟喹酚缩合的生物相容的反向偶氮偶合反应,它与氟喹啉丙氨酸的遗传编码一起,将使我们能够将偶氮苯位点-特异性地引入GLP-1R的两个调控区。在没有或存在GLP-1的情况下,可逆光开关对GLP-1R活性的影响将被用b-arrestin-mCherry作为受体激活的报告来评估。这些研究将为GLP-1R/GCGR激活机制提供关键的见解,这对于开发GLP-1R/GCGR双激动剂作为治疗糖尿病和肥胖症的药物至关重要。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Qing Lin其他文献
Qing Lin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Qing Lin', 18)}}的其他基金
Development of Orally Administered Peptide Hormones for Treatment of Diabetes and Obesity
用于治疗糖尿病和肥胖症的口服肽激素的开发
- 批准号:
10323876 - 财政年份:2021
- 资助金额:
$ 35.15万 - 项目类别:
Development and Applications of Bioorthogonal Chemistry
生物正交化学的发展与应用
- 批准号:
10543732 - 财政年份:2019
- 资助金额:
$ 35.15万 - 项目类别:
Development and Applications of Bioorthogonal Chemistry: Administrative Supplement for Equipment
生物正交化学的发展与应用:设备管理补充
- 批准号:
10581256 - 财政年份:2019
- 资助金额:
$ 35.15万 - 项目类别:
Development and Applications of Bioorthogonal Chemistry
生物正交化学的发展与应用
- 批准号:
10317075 - 财政年份:2019
- 资助金额:
$ 35.15万 - 项目类别:
Development and Applications of Photoinducible Bioorthogonal Chemistry
光诱导生物正交化学的发展及应用
- 批准号:
8240114 - 财政年份:2009
- 资助金额:
$ 35.15万 - 项目类别:
Development and Applications of Bioorthogonal Chemistry
生物正交化学的发展与应用
- 批准号:
8913203 - 财政年份:2009
- 资助金额:
$ 35.15万 - 项目类别:
Development and Applications of Bioorthogonal Chemistry
生物正交化学的发展与应用
- 批准号:
9309042 - 财政年份:2009
- 资助金额:
$ 35.15万 - 项目类别:
Development and Applications of Photoinducible Bioorthogonal Chemistry
光诱导生物正交化学的发展及应用
- 批准号:
8460102 - 财政年份:2009
- 资助金额:
$ 35.15万 - 项目类别:
Development and Applications of Photoinducible Bioorthogonal Chemistry
光诱导生物正交化学的发展及应用
- 批准号:
7793428 - 财政年份:2009
- 资助金额:
$ 35.15万 - 项目类别:
Development and Applications of Bioorthogonal Chemistry
生物正交化学的发展与应用
- 批准号:
9266090 - 财政年份:2009
- 资助金额:
$ 35.15万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 35.15万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 35.15万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 35.15万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 35.15万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 35.15万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 35.15万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 35.15万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 35.15万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 35.15万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 35.15万 - 项目类别:














{{item.name}}会员




